Docket No.: SYN-0031D1 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Dennie J.M. van den HEUVEL and
Johannes J. PLATTEEUW

: Group Art Unit:

Divisional Application of Serial No.: 09/833,662

: Examiner:

Filed:

September 9, 2003

For:

MODIFIED RELEASE FORMULATIONS CONTAINING A HYPNOTIC

AGENT

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Alexandria, Virginia 22313-1450

Sir:

Pursuant to 37 C.F.R. 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the indicated date. Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, that information cited in the statement is considered to be and/or is material to patentability, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. §120. 1138 OG 37, 38 (May 19, 1992).

applica	tion rel	ied on under 35 U.S.C. §120. 1138 OG 37, 38 (May 19, 1992).					
\boxtimes	§1.53(0 §1.491	This Information Disclosure Statement is being filed (i) within three months of the Use date of a U.S. application other than a CPA continued prosecution application und 3(d) OR (ii) within three months of the date of entry of the national stage as set forth 91 in an international application OR (iii) before the mailing date of a first Office Action of merits. No certification or fee is required. 37 C.F.R. §1.97(b).					
	the ma	This Information Disclosure Statement is being filed more than three months after the ling date AND after the mailing date of the first Office Action on the merits, but before alling date of a Final Rejection OR Notice of Allowance OR an action that otherwise prosecution in the application. 37 C.F.R. §1.97(c).					
		a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).					

Division: Applicati		09/833,662	Docket No.: SYN-0031D1
		b. I hereby state that no item of information in this Statement was cited in a communication from a foreign pat foreign application and, to my knowledge after making reast to any individual designated in 37 C.F.R. §1.56(c) more than filing of this Information Disclosure Statement. 37 C.F.R.	ent office in a counterpart onable inquiry, was known three months prior to the
		c. Attached is our check noin the amount of \$1 under 37 C.F.R. §1.17(p). Please credit or debit Deposit needed to ensure consideration of the disclosed information this paper are attached.	Account No. 16-0607 as
	applica amoun Deposi	This Information Disclosure Statement is being filed after on OR Notice of Allowance OR an action that otherwise tion, but on or before payment of the Issue Fee. Attached is t of \$180.00 in payment of the fee under 37 C.F.R. §1.17(it Account No. 16-0607 as needed to ensure consideration of uplicate copies of this paper are attached. 37 C.F.R. §1.97(d.	closes prosecution in the our check no in the p). Please credit or debit the disclosed information.
		a. I hereby state that each item of information control Disclosure Statement was first cited in a communication from a counterpart foreign application not more than three montainformation Disclosure Statement. 37 C.F.R. §1.97(e)(1).	m a foreign patent office in
		b. I hereby state that no item of information in the Statement was cited in a communication from a foreign part foreign application or, to my knowledge after making reason any individual designated in 37 C.F.R. §1.56(c) more than filing of this Information Disclosure Statement. 37 C.F.R.	ent office in a counterpart able inquiry, was known to three months prior to the
\boxtimes		Copies of the references were cited by or submitted to the C/833,662, filed April 13, 2001, which is relied upon for an §120. Thus, copies of these references are not attached. 37	earlier filing date under 35
	includi	To the extent necessary, a petition for an extension of time made. Please charge any shortage in fees due in connection on the general part of time fees, to Deposit Account 16-0607 and part deposit account.	vith the filing of this paper,
		Respectfully submitted, FLESHNER & KIM, LLP	
		Donald R. McPhail Registration No. 35,811 Mark R. Buscher Registration No. 35,006	

Correspondence Address: P.O. Box 161 Catharpin, VA 20143 703 753-5256 MRB/kdb Date: September 9, 2003

SHEET 1 OF 1

LIST OF PRIOR ART CITED BY APPLICANT					ATTY, DOCKET NO. SYN-0031D1		DIVISIONAL OF APPLN. SERIAL NO. 09/833,662				
					APPLICANT(S) LEMMENS et al.						
(PTO-1449)					FILING DATE GROUP						
U.S. PATENT	DOCUMENTS										
EXAMINER'S INITIALS	*PATENT NO.	*ISSUE DATE	*INVENTOR NAME			CLASS	SUBCLASS	FILI DA			
	3,862,140	01/1975	Zinnes et al.								
	4,382,938	05/1983	Kaplan et al.								
	4,626,538	12/1986	Dusza et al.								
	4,794,185	12/1988	Rossey et al.								
	5,292,461	03/1994	Juch et al.								
-	5,891,891	04/1999	Benincasa								
	6,242,460	06/2001	Ettema et al.								
	6,281,360	08/2001	Ettema et al.						Ī		
· - · · · · · · · · · · · · · · · · · ·	6,309,668	10/2001	Bastin et al.								
	6,248,363	06/2001	Patel et al.								
		U.S. PATE	NT APPLICAT	ΓΙΟΝ	PUBLICATION	IS					
	*PATENT APPLN. PUB. NO.	*PUB. DATE	*APPLICANT		CLASS	SUBCLASS					
	<u> </u>										
EXAMINER'S	<u> </u>	F	OREIGN PATENT	DOC	UMENTS			Trans	ation		
INITIALS	PATENT NO.	DATE	C	TNUO	RY	CLASS	SUBCLASS	Yes	No		
	00/33835	06/2000	wo								
	0 050 563	05/1984	EP								
	0 251 859	11/1990	EP								
OTHER A	ART (Including A	Author, Title,	Date, Pertine	nt P	ages, Publishe	r, Place	of Publication	n, Etc.			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Publisher, Place of Publication, Etc.) Martine Schmitt et al., Imidazo [1,2-b] pyridazines. XXIII* Some 5-Deaza Analogues. Syntheses of Some 2-Aryl-6-(chloro, methoxy or unsubstituted)-3-(variously substituted)imidazo[1,2-a] pyridazines and Their Affinity for Central and Mitochondrial Benzodiazepine Receptors; Aust. J. Chem., 50:719-725 (1997)											
	Giuseppe Trapani et al., Synthesis and binding affinity of 2-Phenylimidazo[1,2-a] pyridazines Derivatives for both Central and Peripheral Benzodiazepine Receptors. A New Series of High- Affinity and selective ligands for the Peripheral Type; J. Med. Chem., 40:3109-3118, (1997)										
P. George et al., "Zolpidem and Related Compiounds: Syntheses, Physical Properties and Structure Activity Relationships"; <i>Imidazopyridines in sleep disorders</i> ; Raven Press, pp 11-23, (1998)											
EXAMINER	118.0		DATE CONSIDERED								

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.